A small number of older studies have demonstrated efficacy for a few antidepressants in cancer care ? namely, mianserin, fluoxetine and paroxetine ? but we lack an evidence base for most of the currently used antidepressants. In their systematic review and meta-analysis in this issue of the role of antidepressants in the treatment of cancer-related depression, Riblet et al.  call for high-quality randomized clinical trials that properly examine the efficacy, tolerability and safety of modern-day antidepressants.
|Pages (from-to)||553 - 554|
|Number of pages||2|
|Journal||General Hospital Psychiatry|
|Publication status||Published - 2014|